{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036847","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.524337+00:00","generated_at":"2026-06-04T07:18:40.321753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved","bullets":["Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.","Cash and equivalents $271.2M at Dec 31, 2023; plus $81.1M net IPO proceeds in Feb 2024.","Hemophilia A program achieved NHP proof of concept; development candidate nomination expected mid-2024.","Demonstrated CAST system for >10,000 bp targeted integrations and SMART base editors as small as 623 amino acids.","Cash runway supports 2 INDs and 2 additional development candidate nominations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036847","json":"https://secwatch.observer/filing/0000950170-24-036847.json","markdown":"https://secwatch.observer/filing/0000950170-24-036847.md","text":"https://secwatch.observer/filing/0000950170-24-036847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/0000950170-24-036847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/mgx-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:18:40.321753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33628e967b10deca4f44388ff07dfd678296ac91","claim":"Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, Metagenomi, Inc. announced its financial results for the year ended December 31, 2023 and additional business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/0000950170-24-036847-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}